New Delhi, March 20, 2019: The Jan Aushadhi scheme, under which the government provides quality medicines at affordable rates may disrupt around 20 percent of Indian pharmaceutical market sales, says a report.
According to reports published in moneycontrol.com The scheme aims to provide the highest quality drugs at affordable prices, at almost 50-90 percent discount to their branded counterparts.
The report by Edelweiss expects that around Rs 6,000 crore of the Bureau of Pharma PSUs of India (BPPI) drugs could adversely impact around Rs 25,000-30,000 crore branded sales, assuming an average price differential of five times.
India has over 5,000 Jan Aushadhi stores that cover a list of 800 plus drugs, both chronic and acute, across therapies like anti-cancer, anti-infective, reproductive and gastro intestinal medicines.
